Merck & Co. Inc. (MRK) exceeded revenue expectations in the third quarter, driven by growth in oncology and cardiovascular segments. However, the company faced a decline in Gardasil sales due to lower demand in China. Merck also revised its full-year 2024 forecasts, citing a negative impact from business development transactions.